Literature DB >> 26419404

Five-day stability of thawed plasma: solvent/detergent-treated plasma comparable with fresh-frozen plasma and plasma frozen within 24 hours.

Andrea Neisser-Svae1, Laurenz Trawnicek2, Andrea Heger3, Trupti Mehta1, Darrell Triulzi4.   

Abstract

BACKGROUND: Plasma stored refrigerated for up to 5 days after thawing is common practice in many US hospitals. Therefore, clotting factor activities in fresh-frozen plasma (FFP), plasma frozen within 24 hours (PF24), and solvent/detergent-treated plasma (SDP), thawed and stored at 1 to 6°C for up to 5 days, were investigated. STUDY DESIGN AND METHODS: Five A, B, O, and AB units of FFP, PF24, and SDP were thawed and maintained for 5 days at 1 to 6°C. The activity of factor (F)V, FVII, FVIII, protein S (PS), and ADAMTS13 was determined in each unit at baseline and every 24 hours thereafter for 5 days.
RESULTS: After thaw, mean values of the variables tested were within the normal range in all three plasma products although, in SDP, FVIII activity was significantly lower (p = 0.0039). After 5 days of storage all factors significantly declined except for ADAMTS13 activity, which was stable. Mean FVIII and ADAMTS13 activity was comparable in all three plasma products and within the normal range, mean FV activity was significantly lower in FFP and PF24 (p<0.0001) compared to SDP, and mean FVII activity was significantly lower in PF24 (p<0.03) than in FFP or SDP. Mean PS activity was below the normal range in all three plasma products with the lowest values in SDP (p = 0.0001).
CONCLUSION: Over 5 days of refrigerated storage the changes in the measured coagulation factors in FFP, PF24, and SDP are comparable. Clinical follow-up is needed to assess whether slightly lower PS levels in SDP are clinically important.
© 2015 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26419404     DOI: 10.1111/trf.13356

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Thawing of Pooled, Solvent/Detergent-Treated Plasma octaplasLG®: Validation Studies Using Different Thawing Devices.

Authors:  Andrea Heger; Katharina Pock; Jürgen Römisch
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

Review 2.  Novel blood derived hemostatic agents for bleeding therapy and prophylaxis.

Authors:  Shailaja Hegde; Yi Zheng; Jose A Cancelas
Journal:  Curr Opin Hematol       Date:  2022-08-03       Impact factor: 3.218

3.  Stability of Thawed Apheresis Fresh-Frozen Plasma Stored for up to 120 Hours at 1°C to 6°C.

Authors:  William P Sheffield; Varsha Bhakta; Qi-Long Yi; Craig Jenkins
Journal:  J Blood Transfus       Date:  2016-11-24

Review 4.  Optimizing transfusion strategies in damage control resuscitation: current insights.

Authors:  Timothy H Pohlman; Alison M Fecher; Cecivon Arreola-Garcia
Journal:  J Blood Med       Date:  2018-08-20

5.  Plasma Transfusion Practice in Adult Surgical Patients: Systematic Review of the Literature.

Authors:  Elisabeth Hannah Adam; Dania Fischer
Journal:  Transfus Med Hemother       Date:  2020-09-18       Impact factor: 3.747

6.  Prolonged (post-thaw) shelf life of -80°C frozen AB apheresis plasma.

Authors:  Tim W H Rijnhout; Femke Noorman; Bob De Kort; Margreet Zoodsma; Rigo Hoencamp
Journal:  Transfusion       Date:  2020-07-21       Impact factor: 3.157

7.  Resuscitation of Endotheliopathy and Bleeding in Thoracic Aortic Dissections: The VIPER-OCTA Randomized Clinical Pilot Trial.

Authors:  Jakob Stensballe; Annette G Ulrich; Jens C Nilsson; Hanne H Henriksen; Peter S Olsen; Sisse R Ostrowski; Pär I Johansson
Journal:  Anesth Analg       Date:  2018-10       Impact factor: 5.108

8.  Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasma.

Authors:  Jose A Cancelas; Shawnagay Nestheide; Neeta Rugg; Anna Eckerman; Victor W Macdonald; Matthew L Charles; Luke Markstrom; Andrew J Atkinson; Melissa R King; Michele Snyder; David Burgess; James Murto; Manoj K Valiyaveettil; Joan C Pehta; Stephen A Penegor
Journal:  Transfusion       Date:  2021-12-24       Impact factor: 3.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.